胃腺癌Her-2蛋白表达差异及临床意义分析  

Expression differences of Her-2 protein in gastric adenocarcinoma and its significance

作　　者：李小燕[1] 李雯[1] 姚梅宏[1] 郑宇辉[1] 康德勇[1] 杨映红[1] 

机构地区：[1]福建医科大学附属协和医院病理科,福州350001

出　　处：《福建医药杂志》2015年第5期64-67,共4页Fujian Medical Journal

摘　　要：目的通过检测表皮生长因子受体2(Her-2)蛋白在胃腺癌中的表达状态,探讨Her-2表达在胃腺癌患者中的病理特征及临床意义。方法收集手术切除的胃腺癌样本100例,应用Hercep-Test TM Kits免疫组织化学染色法检测表Her-2蛋白表达水平。结果 Her-2蛋白IHC3+总体阳性率8%,其在胃底-体部腺癌中阳性率高于胃窦部(P=0.046),在高-中分化胃腺癌中的阳性率高于低分化癌(P=0.039);与其他临床病理参数比较,差异无统计学意义(P>0.05)。结论Her-2蛋白检测可为靶向治疗提供用药指导;Her-2蛋白在胃腺癌中表达差异的临床意义仍存在争议,需建立统一规范的实验室控制体系,并扩大样本更深入研究。Objective To detect the status of Her‐2 protein in gastric adenocarcinoma ,and discuss the relationship be‐tween Her‐2 expression differences and clinic‐pathological features of gastric adenocarcinoma .Methods To collect 100 surgical specimens of gastric adenocarcinoma and quantify the Her‐2 protein level by immunohistochemistry （IHC） .Results The overall positive rate of Her‐2 IHC3＋ was 8% .The positive rate was higher in upper stomach body than antrum （P=0.046） ,and was higher in well‐moderate differentiation adenocarcinoma than poor ones （P=0.039） ,while there was no significance between＂Her‐2 level and other clinic‐pathological parameters （P〉0.05） .Conclusion Status of Her‐2 expression in gastric adenocarcino‐ma is still controversial .To establish unified and normative laboratory controls is important for inter‐laboratory comparison on the test results .

关 键 词：胃 腺癌 人类表皮生长因子受体2 免疫组织化学法 

分 类 号：R735.2[医药卫生—肿瘤]